# US 2025/0146069 A1 · Anchored primary nucleic acid probes and methods thereof; ribonuclease-insensitive methods for determining cellular nucleic acid in a biological sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146069 A1
- Document ID: US20250146069A1
- Status: Published application
- Kind: A1
- Application number: 18/938,690
- Filed: 2024-11-06
- Published: 2025-05-08
- Earliest claimed: 2023-11-06
- Assignees: Vizgen, Inc.
- Applicants: Vizgen, Inc.
- Inventors: Jiang He; Lizhi He
- Web page: https://patentgrep.com/patent/US20250146069A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6841: In situ hybridisation
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 21/6456: {Spatial resolved fluorescence measurements; Imaging}
- G01N 21/6458: {Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16)}
- G01N 2021/6432: {Quenching}
- G01N 2021/6441: {with two or more labels}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure is generally directed to anchoring primary nucleic acid probes in a polymer matrix, which are configured to hybridize to cellular nucleic acid, embedding in a polymer matrix, clearing cellular components including the cellular nucleic acid and imaging. The disclosure describes methods for imaging cellular RNA in an RNase insensitive method.

## Claims

### Claim 1

A method of anchoring a primary nucleic acid probe within a matrix and clearing cellular components comprising:
a. contacting a biological sample with a primary nucleic acid probe and an anchoring agent, wherein the primary probe comprises an acrydite moiety and hybridizes with a target nucleic acid and the anchoring agent forms a covalent bond with the primary nucleic acid probe;
b. embedding the biological sample in a polymer matrix wherein the primary nucleic acid probe and the anchoring agent each form a covalent bond with the polymer matrix; and
c. clearing cellular components from the polymer matrix wherein the primary nucleic acid probe hybridized to the target nucleic acid remains anchored in the polymer matrix to form a matrix anchored primary nucleic acid probe sample.

### Claim 2 (depends on 1)

The method of claim 1, further comprising adding RNase to the matrix anchored primary probe sample and clearing the target nucleic acid from the polymer matrix.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anchoring agent is an alkylating agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the alkylating agent is selected from the group consisting of Altretamine, Bendamustine, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine, Ifosfamide, Lomustine, Mechlorethamine, Melphalan, Oxaliplatin, Temozolomide, Thiotepa and Trabectedin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anchoring agent and the primary nucleic acid probe each comprise an acrydite moiety that covalently binds the polymer matrix.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anchoring agent is an alkylating agent derivatized with an acrydite moiety.

### Claim 7 (depends on 1)

The method of claim 1, wherein the target nucleic acid is RNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the target nucleic acid is DNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the primary nucleic acid probe comprises a target sequence that hybridizes to the target nucleic acid, one or more read sequences and an acrydite moiety that covalently binds the polymer matrix.

### Claim 10 (depends on 9)

The method of claim 9, wherein the primary nucleic acid probes are single molecule (sm) FISH probes or multiplexed error robust fluorescence in situ hybridization (MERFISH) probes.

### Claim 11 (depends on 10)

The method of claim 10, further comprising determining read sequences based on contacting the primary nucleic acid probe with a plurality of secondary nucleic acid probes comprising a recognition sequence that hybridizes to the read sequence of the primary nucleic acid probe.

### Claim 12 (depends on 2)

The method of claim 2, further comprising imaging using multiplexed fluorescence in situ hybridization comprising one or more sequential steps of adding a plurality of secondary nucleic acid probes comprising a label moiety that hybridize to the anchored primary nucleic acid probes.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein step a) comprises contacting the biological sample comprising a plurality of distinct RNA species with a plurality of primary nucleic acid probe pools each of the nucleic acid probes comprising a target sequence, one or more read sequences and an acrydite moiety that covalently binds the polymer matrix, wherein each pool of nucleic acid probes hybridize to a distinct RNA species and each pool of probes encode a N-bit code that was assigned to each distinct RNA species, wherein each assigned N-bit code is a valid codeword with a Hamming distance of 2 between valid codewords.

### Claim at position 15

15-48. (canceled)

### Claim 49

A method for imaging a nucleic acid target within a matrix and clearing cellular components comprising:
a. contacting a biological sample with a primary nucleic acid probe and an anchoring agent, wherein the primary probe comprises an acrydite moiety and hybridizes with a target nucleic acid and the anchoring agent forms a covalent bond with the primary nucleic acid probe;
b. embedding the biological sample in a polymer matrix wherein the primary nucleic acid probe and the anchoring agent each form a covalent bond with the polymer matrix;
c. clearing non-target cellular components from the polymer matrix wherein the primary nucleic acid probe hybridized to the target nucleic acid remains anchored in the polymer matrix to form a matrix anchored primary nucleic acid probe sample; and,
d. contacting the anchored primary nucleic acid probe with a plurality of secondary nucleic acid probes comprising a fluorescent label and a recognition sequence that hybridizes to a sequence of the primary nucleic acid probe and imaging the target nucleic acids.

### Claim at position 17

50-156. (canceled)

### Claim 157

A plurality of primary nucleic acid probe pools each of the primary nucleic acid probes comprising: a target sequence, one or more read sequences and an acrydite moiety, wherein each pool of primary nucleic acid probes is configured to hybridize to a distinct RNA species in a sample and each pool of primary probes encode a N-bit code that was assigned to each distinct RNA species, wherein each assigned N-bit code is a valid codeword.

### Claim at position 19

158-167. (canceled)

### Claim 168 (depends on 157)

The primary probe pools of claim 157, wherein the primary nucleic acid probes are covalently bonded to an anchoring agent.

### Claim 169 (depends on 168)

The primary probe pools of claim 168, wherein the anchoring agent is an alkylating agent.

### Claim 170 (depends on 169)

The primary probe pools of claim 169, wherein the alkylating agent is selected from the group consisting of Altretamine, Bendamustine, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine, Ifosfamide, Lomustine, Mechlorethamine, Melphalan, Oxaliplatin, Temozolomide, Thiotepa and Trabectedin.

### Claim 171 (depends on 169)

The primary probe pools of claim 169, wherein the anchoring agent and the primary nucleic acid probes each comprise an acrydite moiety configured to covalently bind a polymer matrix.

### Claim 172 (depends on 168)

The primary probe pools of claim 168, wherein the anchoring agent is an alkylating agent derivatized with an acrydite moiety.

### Claim at position 25

173-184. (canceled)
